Is ipamorelin banned in sport? WADA status

Yes. Ipamorelin is prohibited in sport. The World Anti-Doping Agency (WADA) classifies it under section S2 of its Prohibited List, the section that covers peptide hormones, growth factors, and growth hormone secretagogues^[1]. The ban applies in competition and out of competition, across all sports that operate under the WADA Code. There is no therapeutic use exemption pathway that could plausibly apply, because ipamorelin has no approved indication anywhere in the world.

How section S2 works and why ipamorelin is in it

The WADA Prohibited List is organised into numbered sections. S2, Peptide Hormones, Growth Factors, Growth Hormone Secretagogues and Mimetics, is one of the broadest. It covers not only named substances but also any agent "with a similar chemical structure or similar biological effect(s)" to those named^[1]. Ipamorelin is a ghrelin mimetic: it binds the growth-hormone secretagogue receptor (GHS-R) on the pituitary gland and drives a pulse of growth hormone release, which is the defining mechanism the section targets^[2].

Unlike section S0, which catches any pharmacological agent with no regulatory approval anywhere, S2 is about pharmacological action. A substance falls under S2 because of what it does to the growth hormone axis, not simply because it lacks a marketing authorisation. Ipamorelin satisfies both criteria: it acts as a growth hormone secretagogue and it has no approved therapeutic indication. Athletes need to understand that the S2 classification would survive even if ipamorelin were somehow approved as a medicine for a non-sport-related condition, as long as the pharmacological effect on growth hormone remained.

The named versus catch-all distinction

Some substances on the Prohibited List are named explicitly by generic name within their section. Growth hormone releasing peptides as a class, including ipamorelin, appear in S2 research and anti-doping literature as examples of growth hormone secretagogues covered by the section^[3]. Whether or not a specific substance appears by name in the printed list text, the catch-all language in S2 covers any substance with a similar biological effect to the named agents. A growth hormone secretagogue that drives GHS-R-mediated GH release is inside S2 regardless of whether the word "ipamorelin" appears verbatim. Athletes cannot rely on the absence of a specific name as a signal that a substance is permitted.

What this means for testing and sanctions

Anti-doping laboratories have developed urine-based methods for detecting growth hormone releasing peptides and their metabolites. A 2015 study in Drug Testing and Analysis confirmed that ipamorelin and four other GHRPs can be detected in human urine after nasal administration, with metabolites remaining detectable after the parent compound has cleared^[3]. The detection window for any given test sample depends on the dose, route of administration, and individual pharmacokinetics. Athletes should not assume that subcutaneous administration or low doses make detection less likely.

The practical sanction framework follows the standard WADA Code schedule. A first violation for a prohibited substance in a non-specified substance category carries a default ban of four years. Specified substances carry a two-year default with possible reduction. Whether ipamorelin is classified as specified or non-specified affects the sanction scale; athletes subject to the WADA Code should verify the current classification with their national anti-doping organisation before drawing any conclusions.

The S2 ban is not about performance claims

Ipamorelin's human clinical evidence is limited to short-duration pharmacokinetic characterisation studies from the late 1990s and early 2000s, not efficacy trials^[2]. There is no published phase-2 or phase-3 efficacy trial for any indication. The WADA prohibition does not depend on whether ipamorelin actually improves athletic performance. The Prohibited List targets substances that could confer an advantage (based on pharmacological mechanism) or that pose a risk to athlete health, not only those proven to boost results in sport. Growth hormone secretagogues as a class are on S2 because of the mechanistic potential to elevate growth hormone and downstream IGF-1, which are the same axes targeted by the banned growth hormone (S2.1) itself.

The broader concern about unapproved growth hormone peptides

Eric Topol, writing in Ground Truths in July 2025, grouped ipamorelin with CJC-1295 and tesamorelin as growth hormone related peptides that "carry the potential risk of cancer" on mechanistic grounds, through IGF-1 elevation and broad cell growth signalling^[4]. This is a separate concern from WADA status but reinforces why both regulators and anti-doping bodies treat growth hormone axis peptides as a distinct risk category. For the current US regulatory picture, the FDA Pharmacy Compounding Advisory Committee reviewed ipamorelin's eligibility as a 503A compounding substance at its October 2024 meeting, a process that is separate from and does not change the WADA classification^[5].

What this article does not cover

This piece addresses ipamorelin's status under the WADA Code. It does not cover the country-by-country regulatory picture, the compounding rules, or whether ipamorelin is legal to buy or possess outside of sport. For that, see the ipamorelin peptide page and the country regulation pages. For the broader science and safety profile, the peptide page covers mechanism, pharmacokinetics, and the thin human evidence base in detail.

Competing athletes subject to the WADA Code who are considering ipamorelin should treat it as prohibited. Contact your national anti-doping organisation or the WADA Drug Reference Line for substance-specific guidance. And as with any peptide covered on this site, whether to use ipamorelin in any context is a decision for a clinician who knows your full medical and competition history. See also: ipamorelin regulatory status for the country-by-country approvals picture.